COVID-19 Update: Learn how New York Proton Center is taking all the necessary precautions to keep you safe.

A standard of care, grounded in research

There is a large and compelling body of clinical evidence showing that, for many cancers, proton therapy is overall safer and more effective than conventional radiation, particularly for complex and difficult-to-treat tumors.


And yet, many insurance companies still deny coverage. This is a key reason the New York Proton Center invests so heavily in proton therapy research.


The New York Proton Center has developed a one-of-a-kind research program that aims to further the evidence supporting proton therapy and, in doing so, to make this potentially lifesaving treatment more widely available to patients.


Life Advances®

With its large and productive research division, the New York Proton Center is furthering the body of clinical evidence advancing proton therapy treatment. It is a vibrant hub of activity—laboratory work, clinical trials, translational science, physics research—aimed at producing high quality data, driving best-practice guidelines, and reaffirming proton therapy as a well-established, standard-of-care treatment.

Clinical Trials

As one of its primary objectives, our dynamic research program is working to identify which patients stand to benefit the most from proton therapy. To that end, all patients at the New York Proton Center are given an opportunity to enroll in clinical trials.


Patients interested in participating in any of these trials should speak to their radiation oncologist about eligibility.

The following trials are currently enrolling patients:

Breast Cancer

Proton Collaborative Group BRE 007-12 – Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer: NCT01766297


RadComp: Pragmatic Phase III Randomized Trial of Proton Versus Photon Therapy for Patients with Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: NCT02603341

Gastrointestinal Cancers

A Phase III Randomized Trial of Protons Versus Photons for Hepatocellular Carcinoma. NCT03186898


Phase III Randomized Trial of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal Cancer. NCT03801876

Head and Neck Cancers

Phase II/III Randomized Trial of Intensity-Modulated Proton Beam Therapy (IMPT) Versus Intensity-Modulated Photon Therapy (IMRT) for the Treatment of Oropharyngeal Cancer of the Head and Neck 2012-0825: NCT01893307


Phase II Randomized Study of Proton Versus Photon Beam Radiotherapy in the Treatment of Unilateral Head and Neck Cancer: NCT02923570


Phase II Study of Proton Re-Irradiation for Recurrent Head and Neck Cancer: NCT03217188


Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA): NCT02135042


A Prospective Single Arm Non-Inferiority Trial of Major Radiation Dose De-Escalation Concurrent with Chemotherapy for Human Papilloma Virus Associated Oropharyngeal Carcinoma: NCT03323463

Pediatric Cancers

Proton and Photon Consortium Registry (PPCR): A Multi Center Registry of Pediatric Patients Treated with Radiation Therapy. NCT01696721


Local Control with Reduced-dose Radiotherapy for High-Risk Neuroblastoma: NCT02245997


COG ACNS1422: A Phase II Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients: NCT02724579


COG ACNS1723: A Phase II Study of Dabrafenib (NSC# 763760) with Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAFV600-Mutant High-Grade Glioma (IND# 145355): NCT03919071


COG ANBL1531: A Phase III Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Standard Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma: NCT03126916


COG ARST1431: A Randomized Phase III Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk Rhabdomyosarcoma: NCT02567435


COG ACNS1721: A Phase II Study of Veliparib (ABT-888, IND# 139199) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients with Newly Diagnosed High-Grade Glioma (HGG) without H3 K27M or BRAFV600E Mutations: NCT03581292

Prostate Cancer

COMPPARE: Prospective Comparative Study of Standard IMRT Versus Standard Fractionation Proton Therapy: NCT03561220


Phase II Study of Pencil Beam Scanning Proton Stereotactic Body Radiation Therapy for Prostate Cancer: NCT04842890

Recurrent Cancer

Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors: NCT05313191

Thoracic Cancers

RTOG 1308:  Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC: NCT01993810

All Cancer Types

Proton Collaborative Group REG001-09: Evaluation Tracking Project: A Prospective Chart Review of Patients Treated with Radiation Therapy. NCT01255748

Approved by the FDA since 1988, proton therapy is firmly established as an advanced and highly effective treatment for cancer that can reduce treatment related toxicities, better preserve quality of life, and improve outcomes for patients.

How can we help?

Want to find out if proton therapy might be a good fit for you or your patient? Call us at 833-NYPROTON (833-697-7686) or fill out the appropriate form below.